Iron Bisglycinate for Pediatric Anemia: Tolerability vs Ferrous Sulfate

Iron deficiency is the most common nutritional deficiency in children worldwide, with the WHO estimating that 30–40% of preschoolers in low- and middle-income countries are anemic and around 8–10% of toddlers in high-income countries have iron deficiency. Treatment is straightforward in principle — give iron — but in practice it fails frequently because of GI side effects (constipation, dark stools, vomiting, refusal). Iron bisglycinate, an amino-acid-chelated form, is increasingly used for its tolerability profile. The trial evidence is real but more limited than the marketing suggests.

Why ferrous sulfate is the standard

Ferrous sulfate has been the WHO-recommended pediatric iron supplement for decades. It is cheap, effective, and broadly available. Standard pediatric dosing is 3–6 mg elemental iron per kilogram per day, divided. The most common reasons for treatment failure are tolerability (parents stop giving it because of GI symptoms or staining of teeth) and absorption (taking with milk or calcium reduces uptake). The clinical effectiveness, when adherence is good, is excellent [1].

What iron bisglycinate is

Ferrous bisglycinate is ferrous iron chelated to two glycine molecules. The amino acid chelation protects iron from forming insoluble complexes with phytates and tannins in the gut, and the molecule is absorbed via amino acid transport pathways in addition to the standard ferroportin route. The result is comparable or slightly higher fractional absorption per milligram of elemental iron, with substantially less GI distress in many users [2].

Pediatric trial evidence

A 2014 RCT in Mexican preschoolers compared ferrous bisglycinate (2 mg/kg/day elemental iron) with ferrous sulfate (4 mg/kg/day) for 30 days. Both arms improved hemoglobin similarly, and the bisglycinate arm had significantly fewer GI adverse events [3]. A 2017 trial in Brazilian children with iron deficiency anemia compared bisglycinate and sulfate at equal elemental doses (3 mg/kg/day) for 12 weeks; hemoglobin responses were equivalent and bisglycinate had better tolerability [4]. A larger meta-analysis of pediatric iron supplementation trials including five bisglycinate comparisons reported equivalent efficacy with about half the GI adverse event rate [5].

Where the evidence is thin

Most pediatric bisglycinate trials are 4–12 weeks. There are fewer head-to-head trials in infants under 12 months than in preschoolers. The most rigorous WHO-style trials in resource-limited settings have used sulfate; modifying iron supplementation programs at scale requires more evidence than currently exists, particularly around cost-effectiveness. Bisglycinate costs 3–5× more per mg of elemental iron.

The malaria-endemic question

Iron supplementation in malaria-endemic areas has a long, complicated literature: free iron may favor parasite growth, and the 2006 Pemba trial showed increased mortality in iron-supplemented children in a high-malaria setting [6]. Bisglycinate's chelated form theoretically reduces free iron exposure in the gut, but trials in malaria-endemic areas are sparse and the WHO position remains that iron supplementation should be paired with effective malaria prevention. This is a setting-specific decision, not a general one.

Practical guidance

For an otherwise healthy child with documented iron deficiency anemia and intact follow-up, ferrous sulfate at the WHO-recommended pediatric dose remains first-line. For children who cannot tolerate sulfate — vomiting, severe constipation, or refusal — switching to iron bisglycinate at equivalent elemental dose maintains efficacy with better tolerability. The most important factor in either case is adherence: a tolerated form taken daily beats a "better" form taken intermittently. Hemoglobin should be rechecked at 4–8 weeks and supplementation continued for 3 months after correction to replete stores.

What to look for in the routine follow-up

Hemoglobin alone is an incomplete measure of treatment response. A child started on iron for documented iron deficiency anemia should have hemoglobin, ferritin, and a reticulocyte count rechecked at 4 weeks. Hemoglobin rises by 1 g/dL at 4 weeks in successful treatment; a smaller rise suggests adherence problems, ongoing loss (occult GI bleeding, heavy menstrual periods in adolescents), absorption issues (celiac disease, H. pylori), or wrong diagnosis (thalassemia trait, anemia of chronic disease). After hemoglobin normalises, supplementation continues for 3 months to replete stores, with a final ferritin check before stopping. The most common errors are stopping too soon (relapse within 6 months) and not investigating poor response (missed celiac disease, undiagnosed bleeding source).